-transparent.png){kind=logo}
Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.
Related Publications
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
April 1987,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
January 1986,
Investigational new drugs,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
May 1985,
Cancer treatment reports,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
August 1986,
Onkologie,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
April 1984,
Cancer treatment reports,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
January 1985,
Cancer chemotherapy and pharmacology,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
October 1988,
American journal of clinical oncology,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
February 1991,
British journal of cancer,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
March 1984,
Cancer treatment reports,
J J Kavanagh, and
L J Copeland, and
D M Gershenson, and
P B Saul, and
C L Edwards
September 1988,
Investigational new drugs,
